Navidea Biopharmaceuticals to Announce Third Quarter 2015 Financial Results on November 4, 2015
October 26 2015 - 07:30AM
Business Wire
- Conference call with investment community
to follow at 8:30 a.m. EST -
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced
that the Company will report its financial results for the third
quarter 2015, on Wednesday, November 4, 2015 prior to a conference
call with the investment community scheduled at 8:30 a.m. EST.
Investors and the public are invited to access the live audio
webcast through the link below. Participants who would like to ask
questions during the question and answer session must participate
by telephone also. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The
webcast replay is expected to be available on our investor website,
http://ir.navidea.com, approximately two to four hours after the
live event.
Event: Navidea Biopharmaceuticals Q3 2015 Financial
Results Conference Call Date/Time:
Wednesday, November 4, 2015 at 8:30 a.m.
EST
Webcast Link:
http://edge.media-server.com/m/p/apewz7w6/lan/en
Dial-in Number – US:
(855) 897-5884
Dial in Number – Int’l: (720) 634-2940 Conference ID Number:
64585280 Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immuno-diagnostic agents and
immuno-therapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel immuno-diagnostic agents and
immuno-therapeutics, and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151026005453/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2023 to Mar 2024